Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 9/2014

01-09-2014 | Research Article

Effect of c-erbB2 overexpression on prognosis in osteosarcoma: evidence from eight studies

Authors: Yu Liu, Yun-Hong Ma, Zhen-Zhong Sun, Yong-Jun Rui, Qu-Dong Yin, Sheng Song, Xu-Ming Wei, Jun Liu, Xue-Guang Liu, Ke-Jia Hu

Published in: Tumor Biology | Issue 9/2014

Login to get access

Abstract

C-erbB2 (HER-2/neu) plays an important role in the progression of several types of cancer by increasing tumor growth, migration, invasion, and metastasis and is associated with poor disease prognosis. Numerous studies examining the relationship between c-erbB2 expression and prognostic impact in patients with osteosarcoma have yielded inconclusive results. We therefore conducted a meta-analysis to provide a comprehensive evaluation of the prognostic role of c-erbB2 expression on 5-year survival, which compared the positive and negative expression of c-erbB2 in patients of the available studies. A detailed search was made in PubMed for relevant original articles published in English. Finally, a total of eight studies with 411 osteosarcoma patients were involved to estimate the relationship between c-erbB2 expression and 5-year overall survival. Positive expressions of c-erbB2 predicted poorer survival in osteosarcoma with the pooled RR of 1.53 (95 % CI 1.20–1.94, P = 0.0006). In conclusion, the findings from this present meta-analysis suggest that c-erbB2 overexpression is related to poor prognostic of osteosarcoma and can be a useful clinical prognostic factor for those patients.
Literature
1.
Bertucci F, Araujo J, Giovannini M. Pancreatic metastasis from osteosarcoma and ewing sarcoma: literature review. Scand J Gastroenterol. 2013;48:4–8.CrossRefPubMed
2.
3.
Mirabello L, Troisi RJ, Savage SA. Osteosarcoma incidence and survival rates from 1973 to 2004: data from the surveillance, epidemiology, and end results program. Cancer. 2009;115:1531–43.PubMedCentralCrossRefPubMed
4.
5.
Picci P, Mercuri M, Ferrari S, Alberghini M, Briccoli A, Ferrari C, et al. Survival in high-grade osteosarcoma: improvement over 21 years at a single institution. Ann Oncol Off J Eur Soc Med Oncol ESMO. 2010;21:1366–73.CrossRef
6.
Durnali A, Alkis N, Cangur S, Yukruk FA, Inal A, Tokluoglu S, et al. Prognostic factors for teenage and adult patients with high-grade osteosarcoma: an analysis of 240 patients. Med Oncol. 2013;30:624.CrossRefPubMed
7.
Gill J, Ahluwalia MK, Geller D, Gorlick R. New targets and approaches in osteosarcoma. Pharmacol Ther. 2013;137:89–99.CrossRefPubMed
8.
Gorlick R. Osteosarcoma: clinical practice and the expanding role of biology. J Musculoskelet Nueronal Interact. 2002;2:549–51.
9.
Hynes NE, Lane HA. Erbb receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer. 2005;5:341–54.CrossRefPubMed
10.
Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the her-2/neu oncogene. Science. 1987;235:177–82.CrossRefPubMed
11.
Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, et al. Studies of the her-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244:707–12.CrossRefPubMed
12.
Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, et al. Breast Cancer International Research G: adjuvant trastuzumab in her2-positive breast cancer. N Engl J Med. 2011;365:1273–83.PubMedCentralCrossRefPubMed
13.
Bradburn MJ, Deeks JJ, Berlin JA. Russell Localio A: much ado about nothing: a comparison of the performance of meta-analytical methods with rare events. Stat Med. 2007;26:53–77.CrossRefPubMed
14.
15.
Akatsuka T, Wada T, Kokai Y, Sawada N, Yamawaki S, Ishii S. Loss of erbb2 expression in pulmonary metastatic lesions in osteosarcoma. Oncology. 2001;60:361–6.CrossRefPubMed
16.
Boulytcheva IV, Soloviev YN, Kushlinskii NE, Mahson AN. Expression of molecular markers in the tumor and survival prognosis in osteosarcoma. Bull Exp Biol Med. 2010;150:237–42.CrossRefPubMed
17.
Gorlick R, Huvos AG, Heller G, Aledo A, Beardsley GP, Healey JH, et al. Expression of her2/erbb-2 correlates with survival in osteosarcoma. J Clin Oncol Off J Am Soc Clin Oncol. 1999;17:2781–8.
18.
Gorlick S, Barkauskas DA, Krailo M, Piperdi S, Sowers R, Gill J, Geller D, Randall RL, Janeway K, Schwartz C, Grier H, Meyers PA, Gorlick R, Bernstein M, Marina N (2014) Her-2 expression is not prognostic in osteosarcoma; a children’s oncology group prospective biology study. Pediatr Blood Cancer
19.
Kilpatrick SE, Geisinger KR, King TS, Sciarrotta J, Ward WG, Gold SH, et al. Clinicopathologic analysis of her-2/neu immunoexpression among various histologic subtypes and grades of osteosarcoma. Mod Pathol Off J U S Can Acad Pathol Inc. 2001;14:1277–83.
20.
Onda M, Matsuda S, Higaki S, Iijima T, Fukushima J, Yokokura A, et al. Erbb-2 expression is correlated with poor prognosis for patients with osteosarcoma. Cancer. 1996;77:71–8.CrossRefPubMed
21.
Yalcin B, Gedikoglu G, Kutluk T, Varan A, Akyuz C, Buyukpamukcu M. C-erbb-2 expression and prognostic significance in osteosarcoma. Pediatr Blood Cancer. 2008;51:222–7.CrossRefPubMed
22.
Zhou H, Randall RL, Brothman AR, Maxwell T, Coffin CM, Goldsby RE. Her-2/neu expression in osteosarcoma increases risk of lung metastasis and can be associated with gene amplification. J Pediatr Hematol Oncol. 2003;25:27–32.CrossRefPubMed
23.
24.
25.
Nakajima G, Patino-Garcia A, Bruheim S, Xi Y, San Julian M, Lecanda F, et al. Cdh11 expression is associated with survival in patients with osteosarcoma. Cancer Genomics Proteomics. 2008;5:37–42.PubMed
26.
Nguyen LV, Vanner R, Dirks P, Eaves CJ. Cancer stem cells: an evolving concept. Nat Rev Cancer. 2012;12:133–43.PubMed
27.
Ni C, Zhang Z, Zhu X, Liu Y, Qu D, Wu P, et al. Prognostic value of cd166 expression in cancers of the digestive system: a systematic review and meta-analysis. PLoS One. 2013;8:e70958.PubMedCentralCrossRefPubMed
28.
29.
Park DI, Kang MS, Oh SJ, Kim HJ, Cho YK, Sohn CI, et al. Her-2/neu overexpression is an independent prognostic factor in colorectal cancer. Int J Color Dis. 2007;22:491–7.CrossRef
30.
Yang W, Klos K, Yang Y, Smith TL, Shi D, Yu D. Erbb2 overexpression correlates with increased expression of vascular endothelial growth factors a, c, and d in human breast carcinoma. Cancer. 2002;94:2855–61.CrossRefPubMed
31.
van de Vijver MJ, Peterse JL, Mooi WJ, Wisman P, Lomans J, Dalesio O, et al. Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. N Engl J Med. 1988;319:1239–45.CrossRefPubMed
32.
Ferrari S, Bertoni F, Zanella L, Setola E, Bacchini P, Alberghini M, et al. Evaluation of p-glycoprotein, her-2/erbb-2, p53, and bcl-2 in primary tumor and metachronous lung metastases in patients with high-grade osteosarcoma. Cancer. 2004;100:1936–42.CrossRefPubMed
33.
Ma Q, Zhou Y, Ma B, Chen X, Wen Y, Liu Y, et al. The clinical value of cxcr4, her2 and cd44 in human osteosarcoma: a pilot study. Oncol Lett. 2012;3:797–801.PubMedCentralPubMed
34.
Somers GR, Ho M, Zielenska M, Squire JA, Thorner PS. Her2 amplification and overexpression is not present in pediatric osteosarcoma: a tissue microarray study. Pediatr Dev Pathol Off J Soc Pediatr Pathol Paediatr Pathol Soc. 2005;8:525–32.CrossRef
Metadata
Title
Effect of c-erbB2 overexpression on prognosis in osteosarcoma: evidence from eight studies
Authors
Yu Liu
Yun-Hong Ma
Zhen-Zhong Sun
Yong-Jun Rui
Qu-Dong Yin
Sheng Song
Xu-Ming Wei
Jun Liu
Xue-Guang Liu
Ke-Jia Hu
Publication date
01-09-2014
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 9/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-014-2165-9

Other articles of this Issue 9/2014

Tumor Biology 9/2014 Go to the issue

Research Article

TIMP-3 -1296 T>C and TIMP-4 -55 T>C gene polymorphisms play a role in the susceptibility of hepatocellular carcinoma among women

Research Article

Epigenetic alteration of p16 and retinoic acid receptor beta genes in the development of epithelial ovarian carcinoma

Review

Correlation between fertility drugs use and malignant melanoma incidence: the state of the art

Research Commentary

Comment on Zhuang YF et al.: Impact of vascular endothelial growth factor expression on overall survival in patients with osteosarcoma: a meta-analysis

Research Article

The association between CD14-260C/T polymorphism and malignant tumor risk: a meta-analysis of 5,603 participants

Research Article

TRPM8 promotes aggressiveness of breast cancer cells by regulating EMT via activating AKT/GSK-3β pathway
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits